Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

60.87USD
4:00pm EDT
Change (% chg)

$-0.27 (-0.44%)
Prev Close
$61.14
Open
$61.24
Day's High
$61.40
Day's Low
$60.60
Volume
318,738
Avg. Vol
331,781
52-wk High
$63.64
52-wk Low
$37.37

Latest Key Developments (Source: Significant Developments)

Neurocrine announces FDA approval of 80 mg Ingrezza
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Neurocrine Biosciences Inc : :Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).Says ‍80 mg capsule of Ingrezza will be available for patients within two weeks through a select pharmacy network​.  Full Article

Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences
Friday, 8 Sep 2017 09:00am EDT 

Sept 8 (Reuters) - Neurocrine Biosciences Inc :Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​.  Full Article

Neurocrine Biosciences Q2 loss per share $0.68
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports second quarter 2017 results.Q2 loss per share $0.68.Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.Qtrly ‍total revenues of $6.3 million.  Full Article

Neurocrine Biosciences says on July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28
Wednesday, 12 Jul 2017 05:14pm EDT 

July 12 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences - On July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28, 2016.Neurocrine Biosciences - Amended and restated product agreement finalizes batch sizes and corresponding pricing for 80 mg Ingrezza capsules - SEC Filing.Neurocrine Biosciences - Amended and restated product agreement provides for clarification of testing requirements related to manufacture of Ingrezza.  Full Article

Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules
Wednesday, 5 Jul 2017 07:22am EDT 

July 5 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing.  Full Article

Neurocrine Biosciences reports Q1 loss per share $0.90
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports first quarter 2017 results.Q1 loss per share $0.90.Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.Neurocrine Biosciences Inc says did not report any revenue for Q1 of 2017 compared to $15.0 million of revenue for Q1 of 2016.Neurocrine Biosciences Inc says intends to meet with FDA in late 2017 to discuss a potential new drug application submission.Neurocrine Biosciences -Enrolled subjects in a Phase I safety and pharmacokinetics study exploring NBI-74788 in healthy volunteers that is nearing completion.  Full Article

Neurocrine Biosciences prices $450 mln convertible senior notes offering
Wednesday, 26 Apr 2017 06:48pm EDT 

April 26 (Reuters) - Neurocrine Biosciences Inc :Prices $450.0 million convertible senior notes offering.Priced offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024.  Full Article

Neurocrine announces proposed convertible senior notes offering
Tuesday, 25 Apr 2017 04:01pm EDT 

April 25 (Reuters) - Neurocrine Biosciences Inc -:Neurocrine announces proposed convertible senior notes offering.Neurocrine Biosciences announces intent to offer $450 million of convertible senior notes due 2024 in a private offering.  Full Article

Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules
Tuesday, 11 Apr 2017 04:52pm EDT 

Neurocrine Biosciences Inc : Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules as the first and only approved treatment for adults with tardive dyskinesia (TD) .Neurocrine Biosciences Inc- "Ingrezza will be in distribution channel next week and will be available through a select pharmacy network".  Full Article

Neurocrine Biosciences reports positive results from study of Ingrezza
Tuesday, 21 Mar 2017 08:59am EDT 

Neurocrine Biosciences Inc : Positive results from Kinect 3 phase iii study of Ingrezza (valbenazine) for treatment of tardive dyskinesia (td) . Has submitted NDA to FDA for ingrezza and has been granted priority review with a pdufa action date of April 11, 2017 .Says Ingrezza was found to be generally well tolerated with adverse events consistent with those of prior studies.  Full Article

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)